Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Inc. (NYSE American: PTN) has announced the completion of their Phase 2 clinical trial for an obesity treatment, marking a ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.